Ono Pharmaceutical (OTCMKTS:OPHLF) Stock Crosses Above 50 Day Moving Average – Here’s Why

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $14.86 and traded as high as $15.00. Ono Pharmaceutical shares last traded at $15.00, with a volume of 288 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Zacks Research lowered Ono Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 4th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company currently has a consensus rating of “Hold”.

Ono Pharmaceutical Price Performance

The stock’s 50-day moving average is $14.92 and its 200-day moving average is $14.71. The firm has a market cap of $7.05 billion, a P/E ratio of 14.29 and a beta of 0.33. The company has a quick ratio of 2.86, a current ratio of 3.28 and a debt-to-equity ratio of 0.08.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd. is a Japanese research-driven pharmaceutical company headquartered in Osaka. The company discovers, develops, manufactures and markets prescription medicines, with a focus on oncology, immunology, neurology and other specialty-care areas. Its activities include both internally developed products and collaborations with pharmaceutical and biotechnology companies worldwide.

Ono is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used to treat multiple types of cancer.